Baqsimi™ (glucagon) nasal powder

3mg

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

BAQSIMI™ (glucagon) nasal powder: Use in Pediatric Patients Under the Age of 4 Years

Baqsimi (glucagon nasal powder) is not indicated for the treatment of severe hypoglycemia in pediatric patients under the age of 4 years.

Detailed Information

Baqsimi is not indicated for the treatment of severe hypoglycemia in pediatric patients under the age of 4 years. The safety and effectiveness of Baqsimi have not been established in pediatric patients younger than 4 years of age.1

Baqsimi is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in patients with diabetes ages 4 and above.1

The safety and effectiveness of Baqsimi for the treatment of severe hypoglycemia in patients with diabetes have been established in pediatric patients ages 4 years and above. Use of Baqsimi for this indication is supported by evidence from a study in 48 pediatric patients from 4 to <17 years of age with T1DM.1

Enclosed Prescribing Information

BAQSIMI™ (glucagon) nasal powder, for intranasal use, Lilly

Reference

1. Baqsimi [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.

Glossary

Baqsimi = Baqsimi™ (glucagon) nasal powder

T1DM = type 1 diabetes mellitus

Date of Last Review: August 15, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical